483 Roundup: FDA Cites Italian, Indian and Chinese Firms

Drug GMP Report
A A
The FDA flagged facilities in Italy, India and China for noncompliances including inadequate testing, complaint handling, and quality data, among other violations.

To View This Article:

Login

Subscribe To Drug GMP Report